MAIA Biotechnology (NASDAQ: MAIA) director receives 32,630 stock options grant

Rhea-AI Filing Summary

MAIA Biotechnology director Louie Ngar Yee received a grant of stock options on common shares. The award covers 32,630 options with an exercise price of $1.44 per share, granted under the company’s 2021 Equity Incentive Plan. The options vest 100% on the grant date and are immediately exercisable, expiring on June 30, 2036. Following this grant, Louie Ngar Yee holds 32,630 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Louie Ngar Yee

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	32,630	$0.00	--

Holdings After Transaction: Stock Options — 32,630 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 32,630 options Exercise price: $1.44 per share Expiration date: June 30, 2036 +2 more

5 metrics

Stock options granted 32,630 options Grant on June 30, 2026 to director Louie Ngar Yee

Exercise price $1.44 per share Exercise price of granted MAIA stock options

Expiration date June 30, 2036 Options expire ten years after grant

Post-grant derivative holdings 32,630 derivative securities Total stock options held after transaction

Vesting 100% on grant date Options vest fully on June 30, 2026

Key Terms

Stock Options, 2021 Equity Incentive Plan, exercise price, vest 100% on the date of the grant, +1 more

5 terms

Stock Options financial

"The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

exercise price financial

"conversion_or_exercise_price: "1.4400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest 100% on the date of the grant financial

"representing the right to buy shares of common stock, vest 100% on the date of the grant"

derivative securities financial

"total_shares_following_transaction: "32630.0000" for derivative-type security"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:13 PM Accepted by SEC EDGAR 07/02/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Louie Ngar Yee

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.44	06/30/2026		A		32,630		06/30/2026(1)	06/30/2036	Common Stock	32,630	$0	32,630	D

Explanation of Responses:

1. The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Louie Ngar Yee	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MAIA (MAIA) director Louie Ngar Yee report?

Louie Ngar Yee reported receiving a grant of 32,630 stock options on MAIA common stock. The options were awarded as compensation and are immediately exercisable, giving the right to buy shares at a fixed exercise price of $1.44 per share.

What is the exercise price of Louie Ngar Yee’s MAIA stock options?

The granted stock options carry an exercise price of $1.44 per share. This means Louie Ngar Yee can purchase MAIA common stock at $1.44, regardless of future market price, as long as the options are exercised before their expiration date.

When do Louie Ngar Yee’s MAIA stock options vest and become exercisable?

The stock options vest 100% on the June 30, 2026 grant date and are exercisable beginning that same day. This immediate vesting allows Louie Ngar Yee to exercise the right to buy MAIA common shares as soon as the award is granted.

When do the MAIA stock options granted to Louie Ngar Yee expire?

The stock options granted to Louie Ngar Yee expire on June 30, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase MAIA common stock at the $1.44 exercise price.

How many MAIA derivative securities does Louie Ngar Yee hold after this option grant?

Following this transaction, Louie Ngar Yee holds 32,630 derivative securities related to MAIA common stock. These represent the full amount of the new stock option grant reported, held directly after the award under the company’s 2021 Equity Incentive Plan.